DUS on the Prescribing Indications for CPA/EE in 5 European Countries

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1597 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-06

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:

* prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
* use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
* concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
* second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases

NCT02349399

Acne Vulgaris

COMPLETED

Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

NCT01257984

Contraception

COMPLETED PHASE3

Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation

NCT01103518

Amenorrhea Dysmenorrhea Menstruation Disturbances +1 more

UNKNOWN PHASE4

Risk Minimisation Study for Diane-35 and Its Generics

NCT02410031

Acne Vulgaris

COMPLETED

Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

NCT00195559

Premenstrual Syndrome Menstruation Disturbances

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cyproterone acetate (CPA) 2mg, in combination with ethinyl estradiol (EE) 35mcg, is a medicinal product currently indicated for the treatment of moderate to severe acne in women of reproductive age. Due to the combination with ethinyl estradiol and the dosing, the preparations also act as effective contraceptives.

In 2012, the French health authority conducted a national review of Cyproterone Acetate combined with Ethinyl Estradiol and highlighted serious thromboembolic events and extensive off-label use of these medicines as a contraceptive only. This triggered an Urgent Union Procedure at the beginning of 2013. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the benefits of Cyproterone Acetate combined with Ethinyl Estradiol (cyproterone acetate 2mg / ethinyl estradiol 35mcg) outweigh the risks, providing that several measures are taken to minimize the risk of thromboembolism. These medicines should be used solely for the treatment of moderate to severe acne related to androgen sensitivity and/or hirsutism in women of reproductive age. Since Cyproterone Acetate combined with Ethinyl Estradiol acts as a hormonal contraceptive, women should not take these medicines in combination with hormonal contraceptives. As one of the risk minimization measures, the Market Authorization Holders were required to conduct a number of studies including this drug utilization survey.

This study was a multi-national, cross sectional, prospective, non-interventional, drug utilization study conducted in 5 countries. Study participants were recruited by a network of health care professionals. Physicians collected information from study participants based on questionnaires. This was a one-time survey with no follow-up.

Bayer initiated this study and supported it by an unconditional grant to ZEG. Bayer was not actively involved in the study conduct.

Prolongation of recruitment:

At the beginning of May 2016 the recruitment was finished in 4 of the 5 European countries in which the study was conducted (Austria, Czech Republic, The Netherlands, and Spain). At that point in time, only few patients were enrolled in France because of a delayed recruitment start. Therefore, it was agreed to extend the recruitment phase in France until 31st October 2016, in order to ensure that information on the use of Cyproterone Acetate (combined with Ethinyl Estradiol) would be collected from all participating countries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hirsutism Androgenetic Alopecia Severe Anemia Seborrhea PCOS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cyproterone Acetate and Ethinyl Estradiol

Users of Diane 35 (EE/CPA, BAY86-5264)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during the study period
* Women who are willing to participate in the drug utilization study